Amplitude Surgical (AMPLI) AI Stock Analysis

• Market Cap: €300.13M
• Dividend Yield: N/A
• Average Volume (3M): 10.99K
• Price to Earnings (P/E): 275.3
• Beta (1Y): -0.22
• Revenue Growth: 16.83%
• EPS Growth: N/A
• Country: FR
• Employees: 434
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 48,020,840
• 10 Day Avg. Volume: 10,176
• 30 Day Avg. Volume: 10,995
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: ―

Amplitude Surgical shows positive revenue growth and operational efficiency, but it faces challenges with declining net profit margins and negative cash flows. The stock price exhibits strong bullish momentum, which is a significant positive factor. However, the extremely high P/E ratio indicates overvaluation, which is a concern for potential investors. The lack of earnings call data and corporate events further limits insights into future performance.

Amplitude Surgical Business Overview & Revenue Model

Company Description

Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It offers knee and hip prostheses and implants for the foot and ankle. The company also provides AMPLIVISION, a computer-assisted surgical system; the i.M.A.G.E., a single-use made-to-measure instrument system; and the E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery. In addition, it offers instruments for fitting implants. The company sells its products through a network of distributors and agents in approximately 30 countries. It serves patients, surgeons, and healthcare facilities. Amplitude Surgical SA was founded in 1997 and is headquartered in Valence, France.

How the Company Makes Money

Amplitude Surgical generates revenue through the sale of its orthopedic products, primarily targeting hospitals, clinics, and specialized surgical centers. The company's key revenue streams include sales of knee and hip implants, along with the corresponding surgical instruments and tools. Amplitude Surgical also earns revenue from providing technical support and training to healthcare professionals, ensuring the effective use of its products. Strategic partnerships and collaborations with healthcare institutions and distributors further contribute to its earnings, enabling broader market reach and increased sales volume.

Amplitude Surgical Financial Statement Overview

Summary

Overall, Amplitude Surgical demonstrates growth in revenue and operational efficiency. However, the declining net profit margin and negative free cash flow pose challenges. The balance sheet remains stable, with moderate leverage and a solid equity base. The company should focus on improving profitability and cash flow to strengthen its financial position.

Income Statement

Amplitude Surgical shows positive trends with revenue growth from €87.6M in 2022 to €106M in 2024. Gross profit margin improved slightly to 35.1% in 2024. However, net profit margin decreased significantly from 39.1% in 2023 to 1.4% in 2024 due to a substantial drop in net income. The EBIT and EBITDA margins remain stable, indicating operational efficiency.

Balance Sheet

The balance sheet reflects a stable equity position with stockholders' equity at €95.8M in 2024. The debt-to-equity ratio of 1.24 indicates moderate leverage, offering a balance of risk and stability. The equity ratio is around 34.3%, showcasing a solid equity foundation, though slightly impacted by increased liabilities.

Cash Flow

The cash flow analysis reveals challenges with negative free cash flow of -€6.3M in 2024, though improved from -€11.3M in 2023. Operating cash flow has decreased, reflecting potential liquidity issues. The ratio of operating cash flow to net income is favorable, indicating cash conversion efficiency.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	108.45M	106.02M	100.20M	87.56M	82.71M	88.29M
Gross Profit	37.59M	37.20M	35.73M	27.55M	22.34M	18.17M
EBITDA	27.13M	23.59M	19.03M	19.64M	12.86M	17.37M
Net Income	1.06M	1.53M	39.25M	-4.39M	-14.10M	-14.20M
Balance Sheet
Total Assets	279.66M	279.25M	266.02M	259.46M	269.07M	275.20M
Cash, Cash Equivalents and Short-Term Investments	19.78M	29.10M	37.21M	21.04M	30.68M	36.66M
Total Debt	117.85M	119.13M	106.46M	139.06M	146.76M	141.81M
Total Liabilities	184.97M	183.43M	170.20M	206.89M	212.21M	204.29M
Stockholders Equity	94.70M	95.82M	95.81M	54.18M	58.92M	72.52M
Cash Flow
Free Cash Flow	-4.64M	-6.34M	-11.30M	-4.16M	-7.10M	2.64M
Operating Cash Flow	5.93M	4.04M	8.10M	7.98M	2.34M	12.38M
Investing Cash Flow	-14.79M	-14.42M	45.54M	-12.41M	-9.16M	-9.58M
Financing Cash Flow	-2.40M	2.48M	-37.43M	-5.41M	736.00K	14.76M

Amplitude Surgical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AMPLI, the sentiment is Positive. The current price of 6.25 is above the 20-day moving average (MA) of 6.21, above the 50-day MA of 6.19, and above the 200-day MA of 5.19, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.17 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:AMPLI.

Amplitude Surgical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPLI	64 Neutral	€300.13M	275.33	1.15%	―	16.83%	―
ALERS	60 Neutral	252.64M	63.33	2.24%	―	18.89%	-20.75%
EAPI	50 Neutral	290.31M	-2.33	-13.28%	―	-9.32%	56.88%
MAAT	48 Neutral	66.85M	-1.99	-279.64%	―	52.55%	-2.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%